Five-year outcome is an important landmark in cancer treatment, but until recently, there have been limited data with this length of follow-up in patients with EGFR-mutated locally advanced NSCLC, mainly because of so few patients with the disease. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.